The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention

Am J Perinatol. 2010 Apr;27(4):343-8. doi: 10.1055/s-0029-1243306. Epub 2009 Dec 10.

Abstract

We sought to identify maternal or clinical characteristics of women likely to develop preterm labor (PTL) at <34 weeks' gestation while receiving 17 alpha-hydroxyprogesterone caproate (17P) prophylaxis. Current singleton gestations with prior preterm delivery enrolled for outpatient 17P administration at <27 weeks' gestation were identified ( N = 1177). Maternal and clinical characteristics were compared between women hospitalized and diagnosed with PTL at <34 weeks' gestation (PTL group, N = 270) and those without PTL (No PTL group, N = 660). PTL at <34 weeks' gestation occurred in 270/1177 (22.9%) of patients receiving 17P prophylaxis (mean gestational age at diagnosis was 28.3 +/- 4.0 weeks). Recurrent preterm delivery occurred in 73.3% of women with PTL at <34 weeks. Maternal age, marital status, race, tobacco use, cerclage, gestational age at start of 17P, and Medicaid status were similar between the groups. Women developing PTL at <34 weeks were more likely to have >1 prior preterm delivery than those without PTL (35.2% versus 25.9%, P = 0.006, odds ratio [95% confidence interval] 1.5 [1.1, 2.1]). Women receiving 17P prophylaxis remain at increased risk for PTL and preterm birth. Patient education and surveillance for PTL symptoms may be warranted in women with a history of more than one prior preterm delivery.

Publication types

  • Comparative Study

MeSH terms

  • 17-alpha-Hydroxyprogesterone / administration & dosage*
  • Adult
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Fetal Monitoring / methods
  • Follow-Up Studies
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Obstetric Labor, Premature / chemically induced*
  • Obstetric Labor, Premature / epidemiology
  • Obstetric Labor, Premature / prevention & control
  • Pregnancy
  • Pregnancy Outcome*
  • Pregnancy, High-Risk*
  • Premature Birth / prevention & control*
  • Probability
  • Recurrence
  • Retrospective Studies
  • Risk Assessment

Substances

  • 17-alpha-Hydroxyprogesterone